围手术期肝动脉灌注泵化疗与结直肠癌肝转移切除术后更长生存相关:一项倾向性评分分析
该单中心前瞻性数据库纳入1992至2012年完全切除结直肠癌肝转移的患者,采用倾向性评分匹配7个已知预后因素,比较围手术期肝动脉灌注泵化疗(HAI)与未接受HAI者的总生存(OS)。HAI组中位OS为67个月,未HAI组为44个月(P<.001),倾向性评分校正后HR为0.67(95%CI 0.59-0.76;P<.001)。
要点
- 接受HAI的患者中位OS约延长2年,且该关联独立于现代全身化疗的使用。
- 倾向性评分分析显示HAI与更长OS相关,校正后HR为0.67(95%CI 0.59-0.76;P<.001)。
- 原发肿瘤淋巴结阴性或临床风险评分0-2分的患者似乎从HAI中获益最大。
核心结论
- 接受HAI的患者中位OS比未接受HAI者约长2年,该强关联独立于现代全身化疗的使用,且在倾向性评分分析中依然存在。
研究设计与样本
- 单中心前瞻性维护数据库纳入1992至2012年间完全切除结直肠癌肝转移的患者,所有接受HAI者同时接受围手术期全身化疗,采用倾向性评分匹配7个已知预后因素。
主要发现
- 共2368例连续患者接受完全切除,中位随访55个月;HAI组(n=785)中位OS为67个月,未HAI组(n=1583)为44个月(P<.001),尽管HAI组疾病更晚期。
- 10年OS在HAI组为38.0%,未HAI组为23.8%。
- 接受现代全身化疗的患者(n=1442)中,HAI组中位OS为67个月,未HAI组为47个月(P<.001)。
- 倾向性评分校正后的风险比显示HAI组OS更长:HR 0.67(95%CI 0.59-0.76;P<.001)。
- 原发肿瘤淋巴结阴性患者中位OS为HAI组129个月 vs 未HAI组51个月(P<.001);临床风险评分0-2分患者为HAI组89个月 vs 未HAI组53个月(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To investigate whether perioperative hepatic arterial infusion pump chemotherapy (HAI) was associated with overall survival (OS) in patients who had a complete resection of colorectal liver metastases (CLM). Methods Patients who underwent a complete resection of CLM between 1992 and 2012 were included from a single-center prospectively maintained database. All patients who received HAI also received perioperative systemic chemotherapy. Propensity score analysis was used to match patients for seven known prognostic factors. Results A total of 2,368 consecutive patients underwent a complete resection of CLM, with a median follow-up of 55 months. The median OS for patients with HAI (n = 785) was 67 months versus 44 months without HAI (n = 1,583; P < .001), despite more advanced disease in the HAI group. OS at 10 years was 38.0% versus 23.8% without HAI. For patients who received modern systemic chemotherapy (n = 1,442), the median OS was 67 months with HAI and 47 months without HAI ( P < .001). The hazard ratio adjusted by propensity score demonstrated longer OS with HAI: 0.67 (95% CI, 0.59 to 0.76; P < .001). A pronounced difference in median OS was found for patients with node-negative colorectal cancer (129 months with HAI v 51 months without; P < .001) and a low clinical risk score of 0 to 2 points (89 months with HAI v 53 months without; P < .001). Conclusion Patients who received HAI had a median OS of approximately 2 years longer than patients without HAI. The strong association was independent of the use of modern systemic chemotherapy and remained in propensity score analysis. Patients with node-negative primary tumors or a low clinical risk score seemed to benefit most from HAI.
引用
- Groot Koerkamp B, Sadot E, Kemeny NE, et al. Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. J Clin Oncol. 2017. PMID: 28426374. doi:10.1200/JCO.2016.71.8346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。